Antimicrobial Resistance Market Will Reach USD 9.5 billion By 2032 And registering a CAGR of 7.6%.
Antimicrobial Resistance Market Report 2024 To 2032:
The global antimicrobial resistance market was valued at $4.6 billion in 2022, and is projected to reach $9.5 billion by 2032, registering a CAGR of 7.6% from 2023 to 2032.
The growth of antimicrobial resistance market is attributed to the growing burden of antimicrobial resistance around the globe. This increases the demand for novel medications or antibiotics which are used to treat these drug resistant bacterial infections, which propels the market growth. In addition, misuse and overuse of antibiotics in developing countries such as India and China is also increasing the AMR burden and thus boosting the demand for novel antibiotics.
Request Sample of the Report on:
https://www.alliedmarketresearch.com/request-sample/180698
Antimicrobial Resistance Market Statistics:
- The combination therapies segment to maintain its leadership status throughout the forecast period
- The Escherichia coli segment to maintain its lead position during the forecast period
- The complicated urinary tract infections (cUTI) segment to maintain its lead position during the forecast period
- The cell wall synthesis inhibitors segment to maintain its lead position during the forecast period
- North America to maintain its dominance by 2032.
Economic Downturn Analysis:
- The ongoing global recession had a significant effect on various industries including pharmaceutical and biotechnology industries. Reduced funding in sectors such as pharmaceuticals, biotechnology and chemicals has led to fluctuations in the development of novel antibiotics.
- In addition, it has impacted purchasing decisions for costly medications, potentially affecting the adoption of novel antibiotics.
The growth of the antimicrobial resistance (AMR) market is influenced by several factors, including:
- Increasing Incidence of Infections: As the prevalence of bacterial infections rises, there’s a greater demand for antimicrobial agents, contributing to market growth.
- Inadequate Antibiotic Stewardship: Misuse and overuse of antibiotics lead to the development of resistant strains, necessitating the development of new antimicrobial drugs.
- Evolving Pathogens: Pathogens continually evolve and develop resistance to existing antimicrobial agents, driving the need for novel drugs with different mechanisms of action.
- Globalization and Travel: Increased travel facilitates the spread of resistant pathogens globally, necessitating a coordinated effort to combat antimicrobial resistance.
- Rising Geriatric Population: Elderly individuals are more susceptible to infections and often require antimicrobial treatment, thereby driving market growth.
Drive Your Business Growth Strategy: Purchase the Report for Key Insights
Regional Analysis:
North America held the highest market share in terms of revenue in 2022, accounting for nearly three-fifths of the global antimicrobial resistance market revenue. North America is witnessing notable growth trends, owing to its well-developed healthcare industry and easy availability of advanced medical solutions.
Asia-Pacific region is anticipated to be the fastest growing region estimated to display the fastest CAGR of 8.4% from 2023 to 2032, which is attributed to the large population base in countries such as China and India, rising healthcare expenditure, huge burden of infectious diseases and developing healthcare infrastructure.
Market Segmentation:
By Indication:
- Complicated Urinary Tract Infections (cUTI)
- Blood stream infections
- Acute bacterial skin and skin structure infections (ABSSSI)
- Hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP)
- Community acquired pneumonia (CAP)
- Others
Drug Class:
- Combination therapies
- Tetracyclines
- Cephalosporins
- Glycopeptides and Lipoglycopeptides
- Oxazolidinones
- Others
By Mechanism of Action
- Protein Synthesis Inhibitors
- Cell Wall Synthesis Inhibitors
- Others
By Pathogen:
- Klebsiella pneumoniae
- Pseudomonas aeruginosa
- Staphylococcus aureus
- Enterococcus Spp
- Escherichia coli
Connect to our Analyst:
https://www.alliedmarketresearch.com/connect-to-analyst/A180214
Leading Market Players:
- Alkem Laboratories Ltd.
- Pfizer Inc.
- Acurx Pharmaceuticals, Inc.
- Basilea Pharmaceutica Ltd
- Cumberland Pharmaceuticals
- Wockhardt Limited.
- Paratek Pharmaceuticals Inc
- Nabriva Therapeutics Plc
- Innoviva, Inc
- Merck And Co., Inc.
CUSTOMIZATION OPTIONS:
- Distributor Landscape Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- ‘Business Profile’ of Key Players
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact Data:
David Correa
1209 Orange Street, Corporation Trust Center, Wilmington, New Castle, Delaware 19801 USA.
Toll Free: +1-800-792-5285| Int’l: +1-503-894-6022
UK: +44-845-528-1300| Hong Kong: +852-301-84916
Editor Details
-
Company:
- The Wire Times
